YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway

Abstract

Background Multi-drug resistance is the major cause of chemotherapy failure in hepatocellular carcinoma (HCC). YAP, a critical effector of the Hippo pathway, has been shown to contribute to the progression, metastasis and invasion of cancers. However, the potential role of YAP in mediating drug resistance remains obscure. Methods RT-qPCR and western blot were used to assess YAP expression in HCC cell lines. CCK-8 assays, flow cytometry, a xenograft tumour model, immunochemistry and GFP-mRFP-LC3 fusion proteins were utilized to evaluate the effect of YAP on multi-drug resistance, intracellular ROS production and the autophagy of HCC cells in vitro and in vivo. Autophagy inhibitor and rescue experiments were carried out to elucidate the mechanism by which YAP promotes chemoresistance in HCC cells. Results We found that BEL/FU, a typical HCC cell line with chemoresistance, exhibited overexpression of YAP. Moreover, the inhibition of YAP by shRNA or verteporfin conferred the sensitivity of BEL/FU cells to chemotherapeutic agents through autophagy-related cell death in vitro and in vivo. Mechanistically, YAP silencing significantly enhanced autophagic flux by increasing RAC1-driven ROS, which contributed to the inactivation of mTOR in HCC cells. In addition, the antagonist of autophagy reversed the enhanced effect of YAP silencing on cell death under treatment with chemotherapeutic agents. Conclusion Our findings suggested that YAP upregulation endowed HCC cells with multi-drug resistance via the RAC1-ROS-mTOR pathway, resulting in the repression of autophagy-related cell death. The blockade of YAP may serve as a promising novel therapeutic strategy for overcoming chemoresistance in HCC. Electronic supplementary material The online version of this article (10.1186/s12935-019-0898-7) contains supplementary material, which is available to authorized users.

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges

“…On the one hand, autophagy can keep the genome stable by removing damaged organelles and misfolded proteins, so it can inhibit the growth of cancerous cells [46]. On the other hand, autophagy provides the tumor with more nutrients, which strengthens the tumor's ability to cope with extreme environments [47,48]. In addition, the unlimited proliferation of tumors is partly due to the inhibition of tumor cell apoptosis.…”

Harnessing the Potential Synergistic Interplay Between Photosensitizer Dark Toxicity and Chemotherapy

“… established an intraperitoneal BPD injection protocol (100 mg kg −1 mouse −1 ) , with one injection every other day for 8 days. These methods have been quickly applied and developed in xenograft or orthotopic mouse models by either intraperitoneal or subcutaneous BPD injection every 2–3 days for 2–3 weeks, and no toxicities in other organs have been reported so far . Based on these reports, we believe that the BPD concentrations (0–20 μ m ) tested in our studies are not far from what would apply in vivo through the intratumoral and intraperitoneal injection methods.…”

“…Benzoporphyrin derivative has been shown to disrupt the YAP/TAZ‐TEAD complex interaction without light activation , thereby blocking YAP‐driven oncogenic growth and overcoming resistance to cisplatin and paclitaxel . Additionally, previous studies have demonstrated that there is crosstalk between the YAP/TAZ signaling and the EGFR pathway , and EGFR can also contribute to drug resistance .…”

Osteoprotegerin prompts cardiomyocyte hypertrophy via FAK/BECLIN1 mediated autophagy inhibition

“…Many chemical compound modulate autophagy through ROS pathway [4,10,13,24]. Thus, we test if ROS scavenger N-acetylcysteine has any role in OPG inhibited autophagy.…”